title: Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge.
abstract: A synthetic cycloimmunogen targeting the HIV-1 coreceptor CCR5 was evaluated for its capacity to induce CCR5-specific Abs with anti-HIV-1 activity in cynomolgus macaques. The cyclic closed-chain dodecapeptide (cDDR5) mimicking the conformation-specific domain of human CCR5 was chemically prepared, in which the Gly-Glu dipeptide links the amino and carboxy termini of the decapeptidyl linear chain (Arg168 to Thr177) derived from the undecapeptidyl arch (Arg168 to Cys178) of extracellular loop-2 in CCR5. The immunization of cynomolgus macaques with the cDDR5-conjugated multiple-Ag peptide (cDDR5-MAP) induced anti-cDDR5 serum production for approximately 15 wk after the third immunization. The antisera raised against cDDR5-MAP reacted with both human and macaque CCR5s, and potently suppressed infection by the R5 HIV-1 laboratory isolate (HIV JRFL), R5 HIV-1 primary isolates (clade A:HIV 93RW004 and clade C:HIV MJ4), and a pathogenic simian/HIV (SHIV SF162P3) bulk isolate in vitro. To examine the prophylactic efficacy of anti-CCR5 serum Ab for acute HIV-1 infection, cynomolgus macaques were challenged with SHIV SF162P3. The cDDR5-MAP immunization attenuated the acute phase of SHIV SF162P3 replication. The geometric mean plasma viral load in the vaccinated macaques was 217.10 times lower than that of the control macaques at 1 wk postchallenge. Taken together, these results suggest that cDDR5-MAP immunization is an effective prophylactic vaccine strategy that suppresses and delays viral propagation during the initial HIV-1 transmission for the containment of HIV-1 replication subsequent to infection.
authors.affiliation: Department of Pharmaceutical Biochemistry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
authors.forename: Shogo
authors.initials: S
authors.lastname: Misumi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nakayama
authors.forename: Masashi
authors.initials: M
authors.lastname: Kusaba
authors.forename: Takaaki
authors.initials: T
authors.lastname: Iiboshi
authors.forename: Ryouzaburo
authors.initials: R
authors.lastname: Mukai
authors.forename: Kuniomi
authors.initials: K
authors.lastname: Tachibana
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nakasone
authors.forename: Mamoru
authors.initials: M
authors.lastname: Umeda
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shibata
authors.forename: Masafumi
authors.initials: M
authors.lastname: Endo
authors.forename: Nobutoki
authors.initials: N
authors.lastname: Takamune
authors.forename: Shozo
authors.initials: S
authors.lastname: Shoji
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D001323:Autoantibodies / Q000276:immunology / Q000494:pharmacology; D015488:HIV Antigens / Q000737:chemistry / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D008252:Macaca fascicularis; D010456:Peptides, Cyclic / Q000737:chemistry / Q000276:immunology; D017434:Protein Structure, Tertiary; D019713:Receptors, CCR5 / Q000737:chemistry / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000187:drug effects / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D001323:Autoantibodies; D015488:HIV Antigens; D010456:Peptides, Cyclic; D019713:Receptors, CCR5; D014614:Vaccines, Synthetic